Sage Therapeutics Inc - Asset Resilience Ratio
Sage Therapeutics Inc (SAGE) has an Asset Resilience Ratio of 70.48% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Sage Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Sage Therapeutics Inc (SAGE) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sage Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sage Therapeutics Inc (SAGE) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $298.08 Million | 70.48% |
| Total Liquid Assets | $298.08 Million | 70.48% |
Asset Resilience Insights
- Very High Liquidity: Sage Therapeutics Inc maintains exceptional liquid asset reserves at 70.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sage Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sage Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Sage Therapeutics Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Sage Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 77.37% | $423.40 Million | $547.22 Million | +0.05pp |
| 2023-12-31 | 77.32% | $682.19 Million | $882.28 Million | -4.49pp |
| 2022-12-31 | 81.82% | $1.11 Billion | $1.36 Billion | +2.48pp |
| 2021-12-31 | 79.33% | $1.45 Billion | $1.83 Billion | +59.03pp |
| 2020-12-31 | 20.31% | $438.47 Million | $2.16 Billion | -61.02pp |
| 2019-12-31 | 81.33% | $881.69 Million | $1.08 Billion | +4.51pp |
| 2018-12-31 | 76.82% | $731.83 Million | $952.71 Million | +36.70pp |
| 2017-12-31 | 40.12% | $212.61 Million | $529.94 Million | -16.48pp |
| 2016-12-31 | 56.60% | $228.96 Million | $404.53 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $189.02 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $129.66 Million | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more